Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection

NCT02959255 is registered in ClinicalTrials.gov with Elpen Pharmaceutical Co. Inc. as lead sponsor.

NCT NCT02959255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02959255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Strategy for the Eradication of H. Pylori Infection
Lead sponsor
Elpen Pharmaceutical Co. Inc.
Phase
Phase 4
Overall status
Completed
Start date
January 30, 2017
Completion date
December 30, 2017
Enrollment
364 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

helicobacter pylori infection